Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.53 |
| ▸ | OGFRL1 | Q5TC84 | 8/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274568 | 0.86 | OPRM1 (0.60) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL998070 | 0.84 | CFTR (0.52) | OPRM1OGFRL1CFTR | |
| SCHEMBL6031806 | 0.84 | OPRM1 (0.53) | OPRM1OGFRL1OPRL1LMNACFTR | |
| SCHEMBL517410 | 0.79 | OPRM1 (0.78) | OPRM1OGFRL1OPRL1LMNACFTR | |
| SCHEMBL10038873 | 0.79 | OPRM1 (0.78) | OPRM1OGFRL1OPRL1LMNACFTR | |
| SCHEMBL10038858 | 0.79 | OPRM1 (0.78) | OPRM1OGFRL1OPRL1LMNACFTR | |
| SCHEMBL2435467 | 0.77 | OPRM1 (0.56) | OPRM1OGFRL1OPRL1LMNACFTR | |
| SCHEMBL2438888 | 0.75 | OPRM1 (0.59) | OPRM1OGFRL1OPRL1CFTROPRD1 | |
| SCHEMBL2437691 | 0.74 | OPRM1 (0.61) | OPRM1OGFRL1OPRL1CFTROPRD1 | |
| SCHEMBL2434962 | 0.74 | OPRM1 (0.56) | OPRM1OGFRL1OPRL1LMNACFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | OPRM1 1743/4885OGFRL1 2821/4885OPRL1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.